These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9143642)

  • 1. Dose dependent effects of yohimbine on methadone maintained patients.
    Hameedi FA; Woods SW; Rosen MI; Pearsall HR; Kosten TR
    Am J Drug Alcohol Abuse; 1997 May; 23(2):327-33. PubMed ID: 9143642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone.
    Rosado J; Walsh SL; Bigelow GE; Strain EC
    Drug Alcohol Depend; 2007 Oct; 90(2-3):261-9. PubMed ID: 17517480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients.
    Stine SM; Southwick SM; Petrakis IL; Kosten TR; Charney DS; Krystal JH
    Biol Psychiatry; 2002 Apr; 51(8):642-51. PubMed ID: 11955464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effectiveness of combined naloxone/lofexidine in opiate detoxification: results from a double-blind randomized and placebo-controlled trial.
    Beswick T; Best D; Bearn J; Gossop M; Rees S; Strang J
    Am J Addict; 2003; 12(4):295-305. PubMed ID: 14504022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine.
    Stine SM; Grillon CG; Morgan CA; Kosten TR; Charney DS; Krystal JH
    Psychopharmacology (Berl); 2001 Mar; 154(3):274-81. PubMed ID: 11351934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonidine and yohimbine in opioid-dependent humans responding under a naloxone novel-response discrimination procedure.
    Oliveto A; Sevarino K; McCance-Katz E; Benios T; Poling J; Feingold A
    Behav Pharmacol; 2003 Mar; 14(2):97-109. PubMed ID: 12658070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine and naloxone interactions in methadone maintenance patients.
    Mendelson J; Jones RT; Welm S; Brown J; Batki SL
    Biol Psychiatry; 1997 Jun; 41(11):1095-101. PubMed ID: 9146820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of yohimbine on naloxone-induced antinociception in a rat model of inflammatory hyperalgesia.
    Tsuruoka M; Hiruma Y; Matsutani K; Matsui Y
    Eur J Pharmacol; 1998 May; 348(2-3):161-5. PubMed ID: 9652330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacological modulation of opiate withdrawal using an up-/down-regulation of the noradrenergic system in opiate-dependent rats.
    Streel E; Dan B; Campanella S; Meyvaert A; Hanak C; Pelc I; Verbanck P
    Int J Neuropsychopharmacol; 2006 Oct; 9(5):621-6. PubMed ID: 16146582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The acceptability, safety, and tolerability of methadone/naloxone in a 50:1 ratio.
    Bell J; Shearer J; Ryan A; Graham R; Korompay K; Rizzo S; Sindhusake D; Somogyi AA
    Exp Clin Psychopharmacol; 2009 Jun; 17(3):146-53. PubMed ID: 19586229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.
    Walsh SL; Strain EC; Bigelow GE
    Addiction; 2003 Apr; 98(4):427-39. PubMed ID: 12653813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial methadone dose in treating opiate addiction.
    Wang RI; Kochar C; Hasegawa AT; Roh BL
    Int J Addict; 1982 Feb; 17(2):357-63. PubMed ID: 7076369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification.
    Bearn J; Gossop M; Strang J
    Drug Alcohol Depend; 1998 May; 50(3):227-32. PubMed ID: 9649976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection.
    Umbricht A; Hoover DR; Tucker MJ; Leslie JM; Chaisson RE; Preston KL
    Drug Alcohol Depend; 2003 Apr; 69(3):263-72. PubMed ID: 12633912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine/naloxone versus methadone and lofexidine in community stabilisation and detoxification: A randomised controlled trial of low dose short-term opiate-dependent individuals.
    Law FD; Diaper AM; Melichar JK; Coulton S; Nutt DJ; Myles JS
    J Psychopharmacol; 2017 Aug; 31(8):1046-1055. PubMed ID: 28631527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
    McCambridge J; Gossop M; Beswick T; Best D; Bearn J; Rees S; Strang J
    Drug Alcohol Depend; 2007 Apr; 88(1):91-5. PubMed ID: 17064857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of lamotrigine on naloxone-precipitated opiate withdrawal.
    Rosen MI; Pearsall HR; Kosten TR
    Drug Alcohol Depend; 1998 Oct; 52(2):173-6. PubMed ID: 9800147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of dextromethorphan in naloxone-precipitated opiate withdrawal.
    Rosen MI; McMahon TJ; Woods SW; Pearsall HR; Kosten TR
    Eur J Pharmacol; 1996 Jul; 307(3):251-7. PubMed ID: 8836612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex and opioid maintenance dose influence response to naloxone in opioid-dependent humans: a retrospective analysis.
    Chopra MP; Feldman Z; Mancino MJ; Oliveto A
    Pharmacol Biochem Behav; 2008 Oct; 90(4):787-96. PubMed ID: 18585405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation and stability of naltrexone oral liquid for rapid withdrawal from methadone.
    Fawcett JP; Morgan NC; Woods DJ
    Ann Pharmacother; 1997 Nov; 31(11):1291-5. PubMed ID: 9391680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.